RS50493B - NOVI ČVRSTI OBLIK MEZOPROGESTINA 11β-[4E-(HIDROKSIIMINOMETIL)-FENIL]-17α-METOKSIMETIL-17β-METOKSI-ESTRA-4,9-DIEN-3-ON - Google Patents

NOVI ČVRSTI OBLIK MEZOPROGESTINA 11β-[4E-(HIDROKSIIMINOMETIL)-FENIL]-17α-METOKSIMETIL-17β-METOKSI-ESTRA-4,9-DIEN-3-ON

Info

Publication number
RS50493B
RS50493B YUP-887/02A YUP88702A RS50493B RS 50493 B RS50493 B RS 50493B YU P88702 A YUP88702 A YU P88702A RS 50493 B RS50493 B RS 50493B
Authority
RS
Serbia
Prior art keywords
hydroxyiminomethyl
estra
dien
methoxymethyl
methoxy
Prior art date
Application number
YUP-887/02A
Other languages
English (en)
Inventor
Detlef Grawe
Peter Hösel
Uwe Müller
Gabriele Winter
Original Assignee
Bayer Schering Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Aktiengesellschaft filed Critical Bayer Schering Pharma Aktiengesellschaft
Publication of YU88702A publication Critical patent/YU88702A/sh
Publication of RS50493B publication Critical patent/RS50493B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Amorfni 11β-[4E-(hidroksiiminometil)fenil]-17α-metoksimetil-17β-metoksi-estra-4,9-dien-3-on (J 867), naznačen time, što se ne mogu videti kristalni refleksi na difraktogramu X-zraka na uzorcima praška (XRPD).Prijava sadrži još 6 patentnih zahteva.
YUP-887/02A 2000-05-23 2001-05-09 NOVI ČVRSTI OBLIK MEZOPROGESTINA 11β-[4E-(HIDROKSIIMINOMETIL)-FENIL]-17α-METOKSIMETIL-17β-METOKSI-ESTRA-4,9-DIEN-3-ON RS50493B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00110887A EP1157996A1 (de) 2000-05-23 2000-05-23 Neue Festkörperformen des Mesoprogestins 11Beta-[4E-(Hydroxyiminomethyl)-phenyl]-17Alpha-methoxymethyl-17Beta-methoxy-estra-4,9-dien-3-on

Publications (2)

Publication Number Publication Date
YU88702A YU88702A (sh) 2006-01-16
RS50493B true RS50493B (sr) 2010-03-02

Family

ID=8168805

Family Applications (1)

Application Number Title Priority Date Filing Date
YUP-887/02A RS50493B (sr) 2000-05-23 2001-05-09 NOVI ČVRSTI OBLIK MEZOPROGESTINA 11β-[4E-(HIDROKSIIMINOMETIL)-FENIL]-17α-METOKSIMETIL-17β-METOKSI-ESTRA-4,9-DIEN-3-ON

Country Status (30)

Country Link
US (1) US7799770B2 (sr)
EP (3) EP1157996A1 (sr)
JP (1) JP2003534350A (sr)
KR (1) KR100553292B1 (sr)
CN (1) CN100384867C (sr)
AT (1) ATE397617T1 (sr)
AU (2) AU5634401A (sr)
BG (1) BG65968B1 (sr)
BR (1) BR0111058A (sr)
CA (1) CA2409869C (sr)
CZ (1) CZ2003620A3 (sr)
DE (1) DE50114012D1 (sr)
DK (1) DK1292607T3 (sr)
EA (1) EA005623B1 (sr)
EC (2) ECSP024358A (sr)
ES (1) ES2307613T3 (sr)
HR (2) HRP20021032B1 (sr)
HU (1) HUP0301956A3 (sr)
IL (2) IL152868A0 (sr)
ME (1) MEP15608A (sr)
MX (1) MXPA02011524A (sr)
NO (1) NO327004B1 (sr)
NZ (1) NZ522768A (sr)
PL (1) PL358789A1 (sr)
PT (1) PT1292607E (sr)
RS (1) RS50493B (sr)
SK (1) SK2922003A3 (sr)
UA (1) UA73988C2 (sr)
WO (1) WO2001090137A2 (sr)
ZA (1) ZA200209322B (sr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10218109A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
DE10218107A1 (de) * 2002-04-23 2003-11-20 Jenapharm Gmbh Verfahren zum Herstellen von Kristallen von Steroiden, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
EP1838717A2 (en) * 2005-01-18 2007-10-03 Teva Gyógyszergyár Zártköruen Muködo Részvenytarsaság Amorphous and crystalline forms of dorzolamide hydrochloride and processes of making same
DE102006018888A1 (de) * 2006-04-18 2007-10-25 Bayer Schering Pharma Ag Verfahren zur Herstellung von 4-[17beta-Methoxy-17alpha-methoxymethyl-3-oxoestra-4,9-dien-11beta-yl]benzaldehyd-(E)-oxims (Asoprisnil)
US20090054387A1 (en) * 2006-04-18 2009-02-26 Detlef Grawe Method for preparing 4-[17beta-methoxy-17alpha-methoxymethyl-3-oxestra-4,9-dien-11beta-yl]benzaldehyde (E)-oxime (asoprisnil)
EP1862468A1 (de) * 2006-06-02 2007-12-05 Bayer Schering Pharma Aktiengesellschaft Kristallines 11beta-(4-Acetylphenyl)-20,20,21,21,21-pentafluor-17-hydroxy-19-nor-17alpha-pregna-4,9-dien-3-on
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4332283A1 (de) * 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19610667C2 (de) * 1996-03-08 1998-04-09 Schering Ag (Z)-11ß-[4-(Dimethylamino)phenyl]17ß-hydroxy-17alpha-(3-hydroxy-1-propenyl)estr-4-en-3-on als kristallines Ansolvat
WO2001009116A2 (en) * 1999-07-29 2001-02-08 Eli Lilly And Company A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3- (4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)- 2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE

Also Published As

Publication number Publication date
ES2307613T3 (es) 2008-12-01
HRP20021032B1 (en) 2008-09-30
SK2922003A3 (en) 2003-08-05
AU5634401A (en) 2001-12-03
CN1430624A (zh) 2003-07-16
CZ2003620A3 (cs) 2003-08-13
CN100384867C (zh) 2008-04-30
WO2001090137A3 (de) 2002-04-04
AU2001256344B2 (en) 2007-01-25
BG107557A (bg) 2004-01-30
BG65968B1 (bg) 2010-07-30
KR100553292B1 (ko) 2006-02-22
NO327004B1 (no) 2009-04-06
WO2001090137A2 (de) 2001-11-29
ZA200209322B (en) 2005-03-10
NO20025613D0 (no) 2002-11-22
NZ522768A (en) 2005-03-24
IL152868A0 (en) 2003-06-24
ECSP024358A (es) 2003-03-31
HRP20080423A2 (en) 2008-10-31
DE50114012D1 (en) 2008-07-17
IL152868A (en) 2009-08-03
ECSP084358A (es) 2008-11-27
EA005623B1 (ru) 2005-04-28
PL358789A1 (en) 2004-08-23
CA2409869C (en) 2009-02-03
EP1292607B1 (de) 2008-06-04
MXPA02011524A (es) 2004-09-10
UA73988C2 (en) 2005-10-17
EA200201192A1 (ru) 2003-06-26
US7799770B2 (en) 2010-09-21
YU88702A (sh) 2006-01-16
BR0111058A (pt) 2003-04-15
AU2001256344B8 (en) 2001-12-03
PT1292607E (pt) 2008-09-15
JP2003534350A (ja) 2003-11-18
HRP20021032A2 (en) 2005-02-28
ATE397617T1 (de) 2008-06-15
HUP0301956A2 (hu) 2003-09-29
CA2409869A1 (en) 2002-11-20
DK1292607T3 (da) 2008-10-13
EP1862469A2 (de) 2007-12-05
EP1292607A2 (de) 2003-03-19
US20040006241A1 (en) 2004-01-08
EP1157996A1 (de) 2001-11-28
HUP0301956A3 (en) 2010-03-29
NO20025613L (no) 2002-11-22
KR20030028742A (ko) 2003-04-10
MEP15608A (en) 2010-06-10

Similar Documents

Publication Publication Date Title
RS50493B (sr) NOVI ČVRSTI OBLIK MEZOPROGESTINA 11β-[4E-(HIDROKSIIMINOMETIL)-FENIL]-17α-METOKSIMETIL-17β-METOKSI-ESTRA-4,9-DIEN-3-ON
HRP20030154B1 (en) Preparation of risperidone
AU1676200A (en) Polyhydroxylated heterocyclic derivatives as anti-coagulants
HUP0300268A3 (en) Herbicidal benzoylpyrazole derivatives, compositions containing the same and their use
AU2002224927A1 (en) Use of substituted imidazoazines, novel imidazoazines, methods for the production thereof, and agents containing these compounds
MA27349A1 (fr) Composition cristalline renfermant de l'escitalopram.
EA200300429A1 (ru) Способ получения порошковых композиций
MY121394A (en) New crystalline forms
AU2001236606A1 (en) 3,4-dihydro-2h-benzo(1,4)oxazine inhibitors of factor xa
IL160045A0 (en) Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues
HK1052346A1 (zh) 有效用作β-2-腎上腺素受體激動劑以及PDE4-抑制劑的化合物
YU39803A (sh) Jedinjenja piperazinilpirazina kao agonisti ili antagonisti serotonin 5ht-2-receptora
MXPA02012076A (es) Compuestos quimicos.
AU2001266575A1 (en) Chemical compounds
MXPA02012160A (es) Composiciones medicinales las cuales contienen derivados de propenona.
WO2002024663A3 (en) Pyrimidine compounds and their use
HK1045990A1 (en) Novel derivatives and analogues of galanthamin.
HK1050998A1 (en) Member for application of ointment and ointment patch employing the same
HUP0300127A3 (en) Nematicidal trifluorobutene-derivatives, their preparation, the novel intermediates composition containing the same and use thereof
AU2001256344A1 (en) Novel solid body forms of mesoprogestin 11beta-[4e-(hydroxyiminomethyl)-phenyl]-17alpha-methoxymethy -17beta-methoxy-estra-4,9-dien-3-one
CA2412596A1 (en) Cyclic gmp-specific phosphodiesterase inhibitors
AU7027100A (en) Novel compounds
DE60001366D1 (de) Orale zusammensetzung enthaltend perlit
MXPA02012400A (es) Heterociclos hetaril-substituidos.
GB0108903D0 (en) Novel crystalline forms of a factor Xa inhibitor